Y Intercept Hong Kong Ltd Sells 29,809 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Y Intercept Hong Kong Ltd lessened its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 79.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,947 shares of the biotechnology company's stock after selling 29,809 shares during the period. Y Intercept Hong Kong Ltd's holdings in Sarepta Therapeutics were worth $993,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Comerica Bank raised its holdings in shares of Sarepta Therapeutics by 489.4% during the 1st quarter. Comerica Bank now owns 3,336 shares of the biotechnology company's stock valued at $432,000 after buying an additional 2,770 shares in the last quarter. Cetera Investment Advisers raised its stake in shares of Sarepta Therapeutics by 27.6% during the first quarter. Cetera Investment Advisers now owns 11,991 shares of the biotechnology company's stock worth $1,552,000 after acquiring an additional 2,590 shares in the last quarter. CWM LLC lifted its holdings in shares of Sarepta Therapeutics by 30.4% in the 2nd quarter. CWM LLC now owns 871 shares of the biotechnology company's stock worth $138,000 after acquiring an additional 203 shares during the last quarter. Envestnet Portfolio Solutions Inc. purchased a new stake in shares of Sarepta Therapeutics in the 2nd quarter valued at $201,000. Finally, Perfromance Wealth Partners LLC grew its holdings in shares of Sarepta Therapeutics by 60.0% during the 2nd quarter. Perfromance Wealth Partners LLC now owns 4,000 shares of the biotechnology company's stock valued at $632,000 after purchasing an additional 1,500 shares during the last quarter. Institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Stock Down 0.6 %

Shares of NASDAQ SRPT traded down $0.76 during midday trading on Friday, hitting $123.71. The stock had a trading volume of 730,756 shares, compared to its average volume of 1,223,790. The business's 50 day moving average is $123.05 and its 200-day moving average is $131.30. Sarepta Therapeutics, Inc. has a 52 week low of $89.92 and a 52 week high of $173.25. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The company has a market cap of $11.82 billion, a P/E ratio of 99.58 and a beta of 0.77.

Insider Transactions at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 1,636 shares of the business's stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the completion of the sale, the director now directly owns 5,880 shares in the company, valued at approximately $738,234. The trade was a 21.77 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 7.70% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on SRPT shares. UBS Group upped their price target on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the company a "buy" rating in a research report on Tuesday, September 17th. Needham & Company LLC reduced their price target on Sarepta Therapeutics from $205.00 to $202.00 and set a "buy" rating on the stock in a research report on Wednesday, November 27th. Raymond James reiterated an "outperform" rating and issued a $150.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, October 10th. Guggenheim raised their target price on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. Finally, HC Wainwright lowered their price target on shares of Sarepta Therapeutics from $80.00 to $75.00 and set a "sell" rating for the company in a report on Tuesday, December 3rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $178.71.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.